Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels

European Journal of Cancer

Volumn 37, Issue 16, 2001, Pages 2040-2049

  Davidson, B ^a   Reich, R ^b,e   Berner, A ^a   Givant Horwitz, V ^b   Goldberg, I ^c   Risberg, B ^a   Kristensen, G B ^a   Trope, C G ^a   Bryne, M ^d   Kopolovic, J ^c   Nesland, J M ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d UNIVERSITY OF OSLO   (Norway)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Immunohistochemistry; Matrix metalloproteinases; mRNA in situ hybridisation; Ovarian carcinoma; Reverse transcription polymerase chain reaction; Serous effusions; Tissue inhibitors of metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADENOCARCINOMA; ARTICLE; CANCER CELL; CANCER TISSUE; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; EFFUSION; ENZYME SYNTHESIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MESOTHELIUM CELL; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ASCITIC FLUID; FEMALE; HUMANS; IN SITU HYBRIDIZATION; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; OVARIAN NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; STROMAL CELLS; SURVIVAL RATE; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL;

EID: 0034779239     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00235-0     Document Type: Article

References (31)

1. Global cancer statistics
2. Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993
3. Prospective on ovarian cancer: Why prevent?
4. Ovarian cancer stages I and II: Predictions and 5-year survival in two decades
5. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: An analysis of 1973-1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina
6. Tumor invasion and the extracellular matrix
7. Molecular aspects of tumor cell invasion and metastasis
8. Changing views of the role of matrix metalloproteinases in metastasis
9. Characterization of Gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: Purification of matrix metalloproteinase 2
10. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells
11. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells
12. Biochemical characterization of primary peritoneal carcinoma cell adhesion, migration, and proteinase activity
13. Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines
14. Increased matrix metalloproteinase-9 activity in human ovarian cancer cells cultured with conditioned medium from human peritoneal tissue
15. Detection of cancer cells in effusions from patients diagnosed with gynecological malignancies-evaluation of five epithelial markers
16. Surface epithelial-stromal tumors
17. Expression of metalloproteinases (MMP) and their inhibitors (TIMP) in adenocarcinoma of the uterine cervix - A study using immunohistochemistry and mRNA in situ hybridization
18. Automated molecular pathology: One-hour in-situ DNA hybridization
19. Complete one-hour immunocytochemistry based on capillary action
20. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma
21. MMP and TIMP expression patterns in pleural effusions of different origins
22. Human pleural effusions are rich in matrix metalloproteinases
23. Expression of 72 kilodalton type IV collagenase (Gelatinase A) in benign and malignant ovarian tumors
24. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors. Possible implications for the role of desmoplastic fibroblasts
25. Expression and activity of MMPS and their regulators in ovarian cancer
26. Stage IV ovarian cancer: Impact of surgical debulking
27. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer
28. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma- evidence of up-regulated Tn and Sialyl Tn antigens expression in effusions
29. Up-regulation of CD44s, but not of CD44v3-10, in ovarian carcinoma cells in malignant effusions
30. E-cadherin and α-, β-, and γ-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions